NCT01657851 - Bioequivalence - Duodart Against Avodart & Omnic | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 23, 2012

Primary Completion Date

December 5, 2012

Study Completion Date

December 5, 2012

Conditions

Prostatic Hyperplasia

Interventions

DRUG

dutasteride/tamsulosin

Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules

DRUG

dutasteride

Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules

DRUG

tamsulosin

Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules

Trial Locations (1)

143964

GSK Investigational Site, Reutov, Moscow Region